JP7819094B2 - ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法 - Google Patents

ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法

Info

Publication number
JP7819094B2
JP7819094B2 JP2022506657A JP2022506657A JP7819094B2 JP 7819094 B2 JP7819094 B2 JP 7819094B2 JP 2022506657 A JP2022506657 A JP 2022506657A JP 2022506657 A JP2022506657 A JP 2022506657A JP 7819094 B2 JP7819094 B2 JP 7819094B2
Authority
JP
Japan
Prior art keywords
aminosterol
compound
optionally substituted
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543242A5 (https=
JP2022543242A (ja
Inventor
デニス バーブット、
マイケル ザスロフ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enterin Inc
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Publication of JP2022543242A publication Critical patent/JP2022543242A/ja
Publication of JP2022543242A5 publication Critical patent/JP2022543242A5/ja
Application granted granted Critical
Publication of JP7819094B2 publication Critical patent/JP7819094B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022506657A 2019-08-02 2020-07-31 ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法 Active JP7819094B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962882358P 2019-08-02 2019-08-02
US62/882,358 2019-08-02
US202063041031P 2020-06-18 2020-06-18
US63/041,031 2020-06-18
PCT/US2020/044390 WO2021025973A1 (en) 2019-08-02 2020-07-31 Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same

Publications (3)

Publication Number Publication Date
JP2022543242A JP2022543242A (ja) 2022-10-11
JP2022543242A5 JP2022543242A5 (https=) 2025-03-21
JP7819094B2 true JP7819094B2 (ja) 2026-02-24

Family

ID=74502413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506657A Active JP7819094B2 (ja) 2019-08-02 2020-07-31 ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法

Country Status (7)

Country Link
US (2) US12503485B2 (https=)
EP (1) EP4007764B1 (https=)
JP (1) JP7819094B2 (https=)
CN (1) CN114929724B (https=)
CA (1) CA3149479A1 (https=)
MX (1) MX2022001449A (https=)
WO (1) WO2021025973A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028810A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Compositions and methods for treating brain-gut disorders
WO2021025974A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Human squalamine derivatives, related compositions comprising the same, and methods of using the same
US20230125585A1 (en) * 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment
WO2021216399A1 (en) * 2020-04-20 2021-10-28 Enterin, Inc. Pulmonary aminosterol compositions and methods of using the same to treat microbial infections
WO2023146842A1 (en) * 2022-01-25 2023-08-03 Enterin, Inc. C25 r and s isomers of aminosterols and methods of making and using the same
CN119768413A (zh) * 2022-06-29 2025-04-04 因特尔公司 氨基甾醇化合物、氨基甾醇-环糊精制剂和使用它们的方法
CN118085053A (zh) * 2022-11-25 2024-05-28 深圳先进技术研究院 以Inx5基因或以Inx5蛋白作为作用靶点的物质的应用
US12570686B1 (en) 2024-11-15 2026-03-10 BAZ Therapeutics, Inc. Chemical structures that control metabolic elimination of aminosterols
CN119770654A (zh) * 2025-01-08 2025-04-08 南京大学 Parp1抑制剂在制备治疗和/或缓解弗里德赖希氏共济失调的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036726A1 (en) 2013-09-10 2015-03-19 Swansea University Deuterated compounds
WO2018050815A1 (fr) 2016-09-15 2018-03-22 Virbac Dérivés amides de squalamine pour le traitement des infections
WO2018050814A1 (fr) 2016-09-15 2018-03-22 Virbac Esters des derivés 3-polyaminés des acides biliaires pour le traitement des infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
WO1994020520A1 (en) 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
AU3512595A (en) 1994-09-13 1996-03-29 Magainin Pharmaceuticals, Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
AU723663C (en) 1995-06-07 2001-11-01 Magainin Pharmaceuticals, Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds
WO2009032321A2 (en) * 2007-09-06 2009-03-12 Genaera Corporation A method for treating diabetes
MX367255B (es) 2012-04-20 2019-08-12 Ohr Pharmaceutical Inc Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
EP2934543B1 (en) 2012-12-20 2018-10-31 Mount Desert Island Biological Laboratory Stimulation and enhancement of regeneration of tissues
GB201303589D0 (en) 2013-02-27 2013-04-10 Univ Swansea Compound and method for the treatment of neurodegenerative conditions
EP3083656A1 (en) * 2013-12-20 2016-10-26 Prevacus Inc. Synthesis of ent-progesterone and intermediates thereof
US20230125585A1 (en) 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment
WO2021025974A1 (en) 2019-08-02 2021-02-11 Enterin, Inc. Human squalamine derivatives, related compositions comprising the same, and methods of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036726A1 (en) 2013-09-10 2015-03-19 Swansea University Deuterated compounds
WO2018050815A1 (fr) 2016-09-15 2018-03-22 Virbac Dérivés amides de squalamine pour le traitement des infections
WO2018050814A1 (fr) 2016-09-15 2018-03-22 Virbac Esters des derivés 3-polyaminés des acides biliaires pour le traitement des infections

Also Published As

Publication number Publication date
EP4007764A4 (en) 2023-08-09
CA3149479A1 (en) 2021-02-11
AU2020324937A1 (en) 2022-03-10
US20260098052A1 (en) 2026-04-09
CN114929724B (zh) 2024-12-10
MX2022001449A (es) 2022-04-06
JP2022543242A (ja) 2022-10-11
EP4007764B1 (en) 2026-01-21
EP4007764A1 (en) 2022-06-08
CN114929724A (zh) 2022-08-19
EP4007764C0 (en) 2026-01-21
WO2021025973A1 (en) 2021-02-11
US12503485B2 (en) 2025-12-23
US20230123701A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
JP7819094B2 (ja) ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法
US20220372066A1 (en) Human squalamine derivatives (ent-06), related compositions comprising the same, and method of using the same
US20200262864A1 (en) Deuterated forms of aminosterols and methods of using the same
TW202027728A (zh) 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
US20240277732A1 (en) Compositions and methods for treating brain-gut disorders
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
EP4427738A2 (en) Dosing protocols and regimens for aminosterol treatment
US20200129528A1 (en) Methods for treating blood pressure conditions using aminosterol compositions
US20210315907A1 (en) Compositions and methods for treating brain-gut disorders
AU2020324937B2 (en) Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same
WO2023146838A1 (en) Methods for treating or preventing neurodegenerative disease using a combination of aminosterols and an insulin compound
US20250381197A1 (en) Regimen for Treating Amyotrophic Lateral Sclerosis Having Onset 24 Months Prior to Treatment
US20240415846A1 (en) Method of treating amyotrophic lateral sclerosis and dosing regimen for same
US20230159582A1 (en) Crystalline forms of squalamine
US20250228873A1 (en) C25 r and s isomers of aminosterols and methods of making and using the same
CN114521142A (zh) 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法
US20200038415A1 (en) Aminosterol compositions and methods of using the same for treating erectile dysfunction
US20200038417A1 (en) Methods and compositions for treating cognitive impairment
WO2025160116A1 (en) Methods of treating amyotrophic lateral sclerosis by oral administration of fasudil

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241125

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260210

R150 Certificate of patent or registration of utility model

Ref document number: 7819094

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150